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Abstract 
Defining the prognosis of individual cancer sufferers remains a significant clinical challenge. 
Here we assessed the ability of high-resolution single telomere length analysis (STELA), 
combined with an experimentally derived definition of telomere dysfunction, to predict the 
clinical outcome of patients with chronic lymphocytic leukaemia (CLL). We defined the 
upper telomere length threshold at which telomere fusions occur and then used the mean of 
the telomere ‘fusogenic’ range as a prognostic tool. Patients with telomeres within the 
fusogenic range had a significantly shorter overall survival (P<0·0001; HR = 13.2 (11.6-
106.4)) and this was preserved in early-stage disease patients (P<0·0001, HR = 19.3 (17.8-
802.5)). Indeed, our assay allowed the accurate stratification of Binet stage A patients into 
those with indolent disease (91% survival at 10 years) and those with poor prognosis (13% 
survival at 10 years). Furthermore, patients with telomeres above the fusogenic mean showed 
superior prognosis regardless of their IGHV mutation status or cytogenetic risk group. In 
keeping with this finding, telomere dysfunction was the dominant variable in multivariate 
analysis. Taken together, this study provides compelling evidence for the use of high-
resolution telomere length analysis coupled with a definition of telomere dysfunction in the 
prognostic assessment of CLL.  
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Introduction 
Diagnostic testing is now available for most common cancers. However, defining the 
prognosis of individual patients remains a significant clinical challenge. This is exemplified 
by the clinical conundrum that is chronic lymphocytic leukaemia (CLL); a disease with a 
heterogeneous clinical course ranging from a few months to many decades (Hallek 2010). 
Although the Binet and Rai staging systems are reliable predictors of outcome between the 
staging groups, they fail to identify good and bad prognostic subsets within each stage. Since 
most patients are diagnosed with early stage disease (Rozman, et al 1997), a number of 
laboratory tests have been developed to predict the clinical course of these patients most 
notably IGHV mutation status, CD38 expression, ZAP70 expression and cytogenetic 
abnormalities (Damle, et al 1999, Dohner, et al 1999, Hamblin, et al 1999, Rassenti, et al 
2004). Unmutated IGHV genes, high CD38 expression, high ZAP70 expression and the 
presence of 17p and 11q deletions are all associated with a bad prognosis (Hamblin, et al 
2002, Rassenti, et al 2004), but none of these individual markers can provide definitive 
prognostic information either alone or in combination. Consequently there is a need to 
identify prognostic tools with the capacity to provide personalised risk assessments. 
Telomeres are nucleoprotein structures that cap the ends of linear eukaryotic chromosomes 
(de Lange 2005). Telomere length is a key determinant of telomeric function and short 
dysfunctional telomeres can drive genomic instability and tumourigenesis in mouse models 
(Artandi, et al 2000). There is now substantial evidence that telomere erosion and fusion 
plays an important role in the pathology of many common human malignancies including 
CLL (Damle, et al 2004, Gertler, et al 2004, Meeker and Argani 2004, Ricca, et al 2007, 
Roos, et al 2008, Rossi, et al 2009). However, the lack of resolution of the currently available 
technologies has hampered progress in translating telomeric assays into clinical practice. A 
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key problem with these technologies is their inability to detect short telomeres within the 
length ranges at which dysfunction and fusion occurs (Aubert, et al 2012, Baird 2005, Lin, et 
al 2010). To address this problem, we have developed single-molecule technologies that 
allow the detection of critically shortened telomeres (Baird, et al 2003, Britt-Compton, et al 
2006) and the characterisation of telomere dysfunction (Capper, et al 2007, Letsolo, et al 
2010). Using these tools, we have demonstrated a link between short telomeres, telomere 
fusion and genomic instability in CLL (Lin, et al 2010). Importantly we showed that a subset 
of early-stage patients exhibited extensive telomere erosion and fusion, indicating that 
telomere shortening and dysfunction can precede clinical progression. In this present study 
we defined, for the first time, the telomere length threshold at which fusion events occur and 
used the fusogenic mean as a prognostic tool in a cohort of 200 CLL patients and an 
independent validation cohort of 121 CLL patients.  
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Methods 
CLL Patients 
Peripheral blood samples from 200 CLL patients were obtained after written informed 
consent had been received in accordance with the Declaration of Helsinki and as approved by 
the South East Wales local research ethics committee (LREC# 02/4806). Patients were 
selected purely on a definitive diagnosis of CLL as defined by IWCLL criteria (Hallek, et al 
2008). Comprehensive clinical information was available for all patients with a median 
follow-up of 5.6 years. All of the samples were collected at, or close to, the time of diagnosis 
(<6 months) from two centres, Cardiff and Birmingham, and staging was based on the Binet 
classification system (Binet, et al 1981). Time to first treatment was defined from date of 
diagnosis to date of first treatment intervention. Progression-free survival was calculated 
from date of diagnosis to the point where disease progressed to a more advanced Binet stage. 
Overall survival was quantified from date of diagnosis to date of death or date of last follow-
up. The CLL patients’ clinical/laboratory characteristics are summarised in Table S1.  
 
CLL validation cohort 
Purified DNA extracted from peripheral blood samples from 121 CLL patients was obtained 
from our collaborators in Hull managed by the Newcastle CLL consortium as part of the 
Newcastle Haematology Biobank (REC ref 07/H0906/109+5). Collection of blood samples 
and clinico-pathologic information from patients was undertaken with informed consent in 
accordance with the tenets of the Declaration of Helsinki. The CLL patients’ 
clinical/laboratory characteristics are summarised in Table S2.  
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Isolation of peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from venous blood of CLL 
patients by density centrifugation using Ficoll-Hypaque (Invitrogen, Paisley, UK). For the 
discovery CLL cohort B-cells were subsequently positively isolated using CD19-labelled 
Dynabeads (Invitrogen, Paisley, UK) (Hewamana, et al 2008). For the CLL validation cohort 
and LRF CLL4 trial cohort, DNA was extracted from unselected PBMC. Cells were stored at 
-20°C as dry pellets prior to DNA extraction. 
 
DNA extraction and single telomere length analysis 
DNA was extracted from using standard proteinase K, RNase A, phenol/chloroform protocols 
or the QIAamp DNA Blood Mini Kit (Qiagen, Manchester, UK). For telomere length 
analysis at the XpYp telomere we used the single telomere length analysis (STELA) assay 
previously described (Baird, et al 2003, Britt-Compton, et al 2006, Capper, et al 2007). 
Briefly genomic DNA was solubilised by dilution in 10mM Tris-HCl PH7.5, quantified by 
Hoechst 33258 fluorometry (BioRad, Hercules, USA) and diluted to 10 ng/µl in 10mM Tris-
HCl pH 7.5. 10 ng of DNA was further diluted to 250 pg/µl in a volume of 40µl containing 
1µM Telorette2 linker and 1 mM Tris-HCl pH 7.5. Multiple PCRs (typically 6 reactions per 
sample) were carried out for each test DNA in 10µl volumes 250pg of DNA, 0.5 µM of the 
telomere-adjacent and Teltail primers, 75mM Tris-HCl pH 8.8, 20 mM (NH4)2SO4, 0.01% 
Tween-20, 1.5 mM MgCl2, and 0.05 U of a 10:1 mixture of Taq (ABGene, Epsom, UK) and 
Pwo polymerase (Roche Molecular Biochemicals, Lewes, UK). The reactions were cycled 
with a Tetrad2 thermocycler (BioRad, USA) under the following conditions: 22 cycles of 
94oC for 15 seconds, 65oC for 30 seconds and 68oC for 8mins. The DNA fragments were 
resolved by 0.5% TAE agarose gel electrophoresis, and detected by Southern hybridisations 
with random-primed α-33P labelled (Ready-To-Go DNA Labeling Beads, GE Healthcare, 
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Little Chalfont, UK) TTAGGG repeat probe, together with a probe to detect the 1 kb 
(Stratagene, La Jolla, USA) and 2.5 kb (BioRad) molecular weight marker. The hybridised 
fragments were detected by phosphorimaging with a Typhoon phosphorimager (GE 
Healthcare, USA). The molecular weights of the DNA fragments were calculated using the 
Phoretix 1D quantifier (Nonlinear Dynamics, Newcastle-upon-Tyne, UK). 
 
Telomere fusion assay 
The telomere fusion assay was carried out as described previously (Capper, et al 2007, 
Letsolo, et al 2010). PCR reactions were carried out each containing 100 ng of DNA with 
XpYpM, 17p6 and 21q1 PCR primers (Letsolo, et al 2010). Fusion molecules were detected 
by Southern blotting and hybridisation with the XpYp, 17p and 21q telomere-adjacent probes 
as described previously (Capper, et al 2007, Letsolo, et al 2010). Any fusion products were 
then re-amplified for direct sequence analysis using nested PCR primers (XpYpO, 17p7 and 
21qseq1). 
 
Statistical methods 
Statistical analysis was carried out using Prism 6.0 (Graphpad Software Inc., La Jolla, USA) 
and SAS version 9.3 software (SAS Institute, Marlow, UK). Univariate comparisons for 
overall survival (OS) were conducted with the log-rank test and displayed as Kaplan Meier 
curves. Analyses of time to event outcomes with respect to continuous variables or those with 
less than two categories, together with multivariable analyses, were performed using a Cox 
proportional hazard model with forward selection. P<0.05 was considered significant.  
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Results 
Telomere length and fusion analysis 
We evaluated the telomere length distributions in 200 CLL patients using single telomere 
length analysis (STELA) at the XpYp telomere (Fig. 1A). STELA allows complete resolution 
of telomere lengths at specific chromosome ends (Baird, et al 2003, Capper, et al 2007). We 
analysed the XpYp telomere because our previous data indicate that it is representative of the 
genome-wide telomere length (Baird, et al 2006, Baird, et al 2003) and that telomerase-
expressing cells can homogenise telomere lengths at different chromosome ends (Britt-
Compton, et al 2009, Lin, et al 2010). We previously showed that telomere end-end fusion 
events can be detected in CLL patients with short telomeres (Lin, et al 2010), so we 
systematically assayed for telomere fusions starting with the CLL samples with the shortest 
telomere length distributions. We only considered a fusion event to be bone fide when it 
could be fully characterized by direct DNA sequence analysis (Fig. 1B, 1C and Fig. S1). 
Telomere fusions were detectable in samples derived from all Binet stages, suggesting that 
they are not merely a characteristic of advanced stage disease (Fig. 1D; fusions marked in 
red). Furthermore, the radical telomere shortening seen in this study was completely distinct 
from natural telomere erosion observed as a function of age. To reinforce this point, we found 
no association between telomere length and patient age in our study (r2 = 0·004). Fusion 
events were not detected in samples with a mean XpYp telomere length of >3.81 kb and so 
this upper threshold of telomere dysfunction allowed us to define, for the first time, the full 
extent of the ‘fusogenic’ range in a human cancer population. The mean telomere length of 
the patient subset in which we detected fusions was 2.26 kb (Fig. 1E) and the fusogenic range 
was (0.44 kb – 3.81 kb). We next assessed the impact of the fusogenic mean as prognostic 
marker in our cohort and compared its performance with established clinical and laboratory 
prognostic markers.  
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Telomere dysfunction improves prognostic resolution in terms of TTFT and PFS  
In keeping with previous studies (Damle, et al 2004, Roos, et al 2008, Rossi, et al 2009), 
categorisation by mean telomere length (3.9 kb) was prognostic in our discovery cohort for 
both time to first treatment (TTFT) and progression-free survival (PFS) (Fig. 2A and 2B 
respectively). However, categorisation of the samples above and below the telomere 
fusogenic mean significantly improved the prognostic discrimination of telomere length 
measurement for TTFT and PFS (Fig. 2C and 2D) and segregation of the cohort based on the 
upper limit of fusions (≤/>3.81 kb) also enhanced the prognostic discrimination of mean 
telomere length measurement (Fig. 2E and 2F). 
 
Telomere dysfunction is strongly predictive of overall survival even in stage A patients 
Patients with telomeres below the fusogenic mean (≤2.26 kb) had significantly shorter overall 
survival (Fig. 3A) when compared to patients above the fusogenic mean (HR = 13.2 (11.6-
106.4); P<0.0001). Furthermore, this was also true for patients with early stage disease (HR = 
19.3 (17.8-802.5); P<0.0001, Fig. 3B). These findings confirm that telomere erosion and 
dysfunction can precede clinical disease progression and importantly they allow the accurate 
stratification of Binet stage A patients into those with indolent disease course and those with 
a consistently poor prognosis. 
 
Validation of telomere dysfunction in an independent cohort of CLL patients 
Given the striking findings from our discovery cohort, we set out to validate our results in an 
independent cohort of CLL patients derived from a different centre. We performed STELA 
on an additional 121 unselected CLL samples in a blinded fashion and subsequently analysed 
the impact of the fusogenic mean on survival for the whole cohort and the stage A patients. 
10	  
	  
Figures 3C and 3D show that the prognostic impact of telomere dysfunction was clearly 
evident in the total cohort (P<0.0001; HR = 7.4 (6.9-96.3)) and the stage A cohort (P<0.0001; 
HR = 8.9 (7.0-320.7)). These findings support the results from the discovery cohort and 
confirm the prognostic potential of telomere dysfunction in CLL. Furthermore, univariate 
analysis of the combined discovery and validation cohorts (n = 321) revealed that the 
fusogenic mean was associated with markedly increased hazard ratios signifying improved 
prognostic power for PFS and OS than all of the established clinical and laboratory markers 
evaluated including IGHV mutation status, CD38 expression, ZAP-70 expression, 
fluorescence in situ hybridisation cytogenetics and beta-2 microglobulin.  These data are 
summarised in Table 1.  
 
Recursive partitioning identifies the 2.26 kb threshold as most prognostic for survival 
Although we had experimentally determined the telomere length threshold for telomere 
dysfunction in CLL, we wanted to establish if it represented the optimal telomere length cut-
off for predicting survival in our cohort. We therefore performed recursive partitioning of the 
dataset and revealed that telomere length cut-offs within our defined fusogenic range (≤3.81 
kb) were highly prognostic when compared to the established prognostic markers, there was a 
consistent increase in hazard ratio at 2.26 kb demonstrating that this telomere length was the 
most prognostic threshold in the discovery and validation cohorts (Fig. 3E and 3F 
respectively).  
 
Telomere dysfunction enhances the prognostic impact of established prognostic 
markers 
Kaplan Meier curves showing the performance of the established prognostic markers in the 
combined discovery and validation CLL cohort are given in Fig. S2. These markers provided 
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similar prognostic power to that described in previous studies (Damle, et al 1999, Dohner, et 
al 1999, Hamblin, et al 1999, Rassenti, et al 2008) but all of the markers were considerably 
less prognostic as evidenced by lower hazard ratios than the telomere fusogenic mean. We 
therefore assessed whether the fusogenic mean could provide additional prognostic 
information in the context of established good and bad prognostic subsets. In every case, the 
telomere fusogenic mean contributed the dominant effect. For example, patients with 
telomeres below the fusogenic mean showed inferior prognosis regardless of their IGHV 
mutation status. Similarly, patients with telomeres above the fusogenic mean showed superior 
prognosis regardless of their IGHV mutation status. This effect was also observed in patients 
with 11q- or 17p- cytogenetic lesions i.e. the adverse clinical impact of these abnormalities 
was only evident in the patients with short telomeres (Fig. 4). 
 
Telomere length is the dominant co-variable in multivariate analysis 
In order to test the independent prognostic value for telomere dysfunction in CLL prognosis, 
we next performed multivariate analysis on the combined CLL dataset using Cox 
proportional hazards regression with forward selection.  The variables included in the model 
were age at diagnosis, Binet stage at diagnosis, telomere fusogenic mean, IGHV mutation 
status, CD38 expression, ZAP70 expression, cytogenetics. The telomere fusogenic mean was 
associated with the highest hazard of progression and death independent of all other 
established biomarkers. Table 2 shows the co-variables included in the model in order of 
importance. When the telomere fusogenic mean was entered in the model, only IGHV 
mutation status and Binet stage retained independent significance for PFS and only CD38 
expression retained independent significance for OS in the model; no other parameters met 
the P<0.05 level for inclusion once the fusogenic mean was entered into the model.   
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Discussion 
 
We have recently provided the first direct demonstration that human tumour cells can 
develop telomere dysfunction and undergo a ‘telomere crisis’ that drives genomic instability 
and clonal evolution (Lin, et al 2010). Given this finding, we set out to establish the 
prognostic significance of telomere dysfunction in a large unselected cohort of CLL patients 
(n = 200). As a first step, we identified the upper limit of detection of telomere fusion events 
allowing us to accurately define, for the first time, the fusogenic range in a primary human 
malignancy. We then used the mean of the fusogenic range (2.26 kb) to categorise the patient 
cohort. This new definition of telomere dysfunction transformed the prognostic power of 
telomere length analysis into the most prognostic parameter ever described in CLL, a finding 
that was subsequently confirmed in an independent validation cohort of 121 CLL patients. 
Recursive partitioning of our data independently confirmed that 2.26 kb was the most 
prognostic threshold in both the discovery and validation cohorts providing further evidence 
that it represents the biologically important threshold of telomere stability in CLL.   
 
The molecular basis of the extensive telomeric erosion observed in some CLL patients 
remains largely unexplained. However, given that it can precede disease progression it must 
represent an early event in the pathology of this disease at least in some patients. A number of 
recent publications have highlighted somatic mutations in POT1, (Ramsay, et al 2013, 
Robles-Espinoza, et al 2014) a protein critical for telomere capping, as driver mutations in 
CLL and malignant melanoma offering a mechanistic rationale for telomeric fusion events. 
However, POT1 mutations appear to be exclusively associated with unmutated IGHV genes 
in CLL (Ramsay, et al 2013). Therefore they cannot provide a neat explanation for the 
critically short telomeres observed in this study as only 49% of cases with telomeres within 
the fusogenic range had unmutated IGHV genes. 
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A number of previous studies using QPCR, TRF or FISH-based techniques have shown that 
mean telomere length can provide useful prognostic information in CLL but only in 
combination with other established markers (Ricca, et al 2007, Roos, et al 2008, Rossi, et al 
2009). As a consequence telomere length assessment has not been adopted as a routine test in 
the clinical management of CLL. However, by using high-resolution STELA analysis and 
applying a telomere length threshold based on telomere dysfunction, we have identified a 
biomarker of clinical outcome in CLL that provides unprecedented prognostic resolution. It is 
worthy of note that as STELA is able to accurately measure telomere lengths within this 
critical fuosgenic range it provides clinical prognostic information beyond the ability of 
QPCR, TRF or FISH-based techniques (Aubert, et al 2012, Baird 2005). Thus, our study 
transforms the utility of telomere length assessment in CLL and allowed accurate prospective 
stratification of Binet stage A patients into those with indolent disease (91% survival at 10 
years) and those with poor prognosis (13% survival at 10 years). The power of telomere 
dysfunction to accurately predict clinical outcome in CLL was further reinforced when we 
performed multivariate analysis on the combined cohort. Telomere dysfunction was the 
dominant co-variable in Cox proportional hazards forward selection modelling. Although 
STELA is a multi-step precision assay, its component parts utilise standard molecular biology 
approaches (PCR and Southern blotting). As such it is no more complex than IGHV mutation 
analysis to perform and is technically much less difficult to perform and interpret than next 
generation sequencing for example. Given the prognostic power of the assay demonstrated 
here there is no technical reason why it should not be amenable to widespread 
implementation in clinical practice. 
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In conclusion our data strongly support the concept that telomere dysfunction is a critical 
determinant of clinical outcome in CLL. Our definition of telomere dysfunction provides 
reliable prognostic information and facilitates, for the first time, confident prediction of 
clinical outcome for individual patients. This will be of particular utility for the majority of 
patients who initially present with early stage disease. As such our data provides compelling 
evidence for the use of high-resolution telomere length analysis coupled with a definition of 
telomere dysfunction in the prognostic assessment of individual CLL patients. 
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Table 1. Univariate comparison of prognostic factors in the combined discovery and 
validation cohorts (n = 321) in terms of overall survival. 
Parameter Progression-free survival Overall survival 
 Median 
(years) 
HR (95%CI) P-value Median 
(years) 
HR (95%CI) P-value 
Fusogenic 
mean  
5.6 
(4.9-46.6) 
<0.0001  
12.8 
(10.0-103.8) 
<0.0001 
≤2.26 kb 2.0   7.2    
>2.26 kb not reached   not reached   
IGHV status  3.8 (2.6-7.9) <0.0001  2.9 (1.9-7.0) <0.0001 
≥98% 2.9   10.0 years   
<98% not reached   not reached   
CD38  2.4 (1.5-4.5) 0.0006  2.3 (1.4 -5.1) 0.003 
≥20% 3.0   not reached   
<20% not reached   not reached   
ZAP-70  2.1 (1.3-2.8) 0.07  1.7 (0.95-3.2) 0.07 
≥20% 6.0   not reached   
<20% not reached   not reached   
β2-M  3.1 (1.6-6.2) 0.001  1.6 (0.69-3.8) 0.28 
≥4 mg/l 3.0   not reached   
<4 mg/l not reached   not reached   
Genetics  4.7 (3.1-14.9) <0.0001  3.8 (2.8-23.4) 0.0001 
11q- / 17p- 2.3   6.9    
N / O not reached   not reached   
 
Fusogenic mean: The mean telomere length of the samples in which fusion events were 
detected 
IGHV status: <98% sequence homology with the closest germline sequence (mutated); ≥98% 
sequence homology with the closest germline sequence (unmutated) 
β2-M: beta-2 microglobulin;  
11q- and 17p-: any FISH or karyotypic abnormality of 11q or 17p  
N: No detectable cytogenetic aberration by FISH; O: Other cytogenetic abnormality 
(excluding 11q- or 17p-) 
HR = Hazard ratio; CI, confidence interval 
95% CI = 95% confidence interval 
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Table 2. Multivariate analysis of the combined discovery and validation CLL cohorts using Cox 
proportional hazards regression with forward selection 
Summary of forward selection in order of inclusion in the model 
Progression-free survival Overall survival 
Effect HR 95% CI p-value Effect HR 95% CI p-value 
Fusogenic 
mean 
5.11 2.39-7.07 <0.0001 
Fusogenic 
mean 
12.86 4.9-33.5 <0.0001 
IGHV 
status 
1.21 1.1-1.32 0.001 
CD38 
expression 
2.67 1.12-6.37 0.026 
Binet stage 
1.52 1.09-2.12 0.012     
 
HR = Hazard ratio 
95% CI = 95% confidence interval 
Variables considered in the model were: age at diagnosis, Binet stage at diagnosis, telomere 
fusogenic mean, IGHV mutation status, CD38 expression, ZAP70 expression, cytogenetics. 
 
Figure Legends 
Figure 1.  Defining telomeric parameters for prognosis in CLL. (A) shows an example of 
STELA at the XpYp telomere in 12 CLL patients in which fusion was, or was not detected as 
indicated above. Mean and standard deviation are displayed below and the means highlighted 
in red on the gel image.  (B) examples of fusion analysis in 4 CLL patients.  (C) examples of 
the DNA sequence of the fusion events highlighted on the fusion gel above. Arrows indicate 
the fusion junction, together with the participating telomere and the deletion from the start of 
the respective telomeres. Homology between the participating telomeres is underlined. (D) 
mean XpYp telomere length data plotted as a function of Binet staging in the discovery 
cohort. Black markers indicate those that were not tested for fusion, blue those that were 
negative and red those that were positive for fusion events.  (E) telomere length data from the 
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discovery cohort, together with those that were positive for fusion events. The mean XpYp 
telomere length of the samples in which fusion was detected was 2.26 kb. 
 
Figure 2. Telomere dysfunction predicts time to first treatment and progression-free 
survival in CLL. (A) and (B) In keeping with previous studies, mean telomere length (as 
measured by STELA) is prognostic for TTFT and PFS respectively. Segregation of the 
discovery cohort into subsets defined by the fusogenic mean (≤2.26 kb) significantly 
enhanced the prognostic resolution for (C) TTFT and (D) PFS. Furthermore, the upper limit 
of fusions (≤3.81 kb) also improved prognostic discrimination for (E) TTFT and (F) PFS) but 
to a less extent than the fusogenic mean. 
  
Figure 3.  Telomere length as defined by fusion is highly prognostic for overall survival 
in CLL. (A) and (B) Kaplan Meier curves for overall survival in the discovery cohort of 200 
CLL patients and the stage A subset (n = 144) respectively. (C) and (D) show Kaplan Meier 
curves for overall survival in the validation cohort of 121 CLL patients and the stage A subset 
(n = 92). P values, Hazard Ratio (HR) and 95% confidence intervals are indicated on the 
plots together with numbers at risk in each arm.  (E) recursive partitioning of mean telomere 
length in our initial dataset and plots the hazard ratios for overall survival for each threshold 
for the entire cohort and the stage A patient subset. (F) recursive partitioning of the validation 
cohort and the stage A subset. In every case 2.26 kb provided the optimal discrimination.  
 
Figure 4.  Telomere dysfunction effectively negates the impact of established prognostic 
markers. Survival curves for concordant and discordant datasets based on telomere 
dysfunction in combination with (A) IGHV status, (B) CD38 status, (C) FISH cytogenetics 
and (D) ZAP70 status in the combined discovery and validation cohort (n = 321). The 
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prognostic effect of telomere dysfunction dominates the analysis to such an extent that it 
effectively removes the negative impact of established poor prognostic markers. 
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